Skip to content

Clinical Performance Evaluation of Sansure Hepatitis C Virus RNA Quantitative Fluorescence Diagnostic Kit (PCR-Fluorescence Probing)

Clinical Performance Evaluation of Sansure Hepatitis C Virus RNA Quantitative Fluorescence Diagnostic Kit (PCR-Fluorescence Probing) - REQA_24005_SNSR_HCV

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00034144
Enrollment
144
Registered
2024-07-24
Start date
2024-07-22
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis C is an inflammation of the liver caused by the hepatitis C virus (HCV). HCV is transmitted through blood, for example through drug use. Hepatitis C is often chronic, but can almost always be cured in a maximum of three months. Without treatment, hepatitis C can lead to liver failure or liver cancer.

Interventions

Group 1: Test device: Hepatitis C Virus RNA Quantitative Fluorescence Diagnostic Kit (PCR-Fluorescence Probing) This is a cross-sectional, observational design study with retrospective/leftover blood

Sponsors

Sansure Biotech Inc.
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: -HBV negative Specificity: -HBV Antigen positive/ negative samples Interference: HBV negative Proben with -Hepatitis A virus (HAV) positive -Human Immunodeficiency Virus (HIV) positive -Hepatitis C virus (HCV) positive -Influenza A virus (IAV) positive -Human Cytomegalovirus (CMV) positive -Candida albicans positive -Epstein-Barr virus (EBV) positive -Treponema pallidum positive -Herpes simplex virus 2 (HHV-2) positive -Staphylococcus aureus positive

Exclusion criteria

Exclusion criteria: -Sample was not frozen -Tube was damaged -No blinding ID

Design outcomes

Primary

MeasureTime frame
diagnostic specificity (DSpec) represented by negative percentage agreement, NPA) Diagnostic Specificity=NPA=B2/((B1+B2)=TN/((FP+TN) ))

Secondary

MeasureTime frame
crossreactivity tested against genomes of: -Hepatitis A virus (HAV) -Human Immunodeficiency Virus (HIV) -Hepatitis C virus (HCV) -Influenza A virus (IAV) -Human Cytomegalovirus (CMV) -Candida albicans -Epstein-Barr virus (EBV) -Treponema pallidum -Herpes simplex virus 2 (HHV-2) -Staphylococcus aureus interference tested in: - Women who have had more than one pregnancy - Rheumatoid factor positive samples - anti- E. coli antibodies - anti-Candida albicans antibodies

Countries

Germany

Contacts

Public ContactHakan Inan

Requalite GmbH

info@requalite.com+49 89 32800304

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 7, 2026